# γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)

> **NCT04028440** · EARLY_PHASE1 · UNKNOWN · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 6 (estimated)

## Conditions studied

- Non-Hodgkin's Lymphoma
- Relapsed or Refractory B Cell Non-Hodgkin's Lymphoma
- Chronic Lymphoblastic Leukemia
- Peripheral T Cell Lymphoma

## Interventions

- **BIOLOGICAL:** Autologous γδT cells

## Key facts

- **NCT ID:** NCT04028440
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-10
- **Primary completion:** 2020-12-31
- **Final completion:** 2022-03-31
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2019-09-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04028440

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04028440, "γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04028440. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*